Peter P Kunambi
Overview
Explore the profile of Peter P Kunambi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
38
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kitua D, Khamisi R, Salim M, Kategile A, Mwanga A, Kivuyo N, et al.
Surg Pract Sci
. 2025 Jan;
11():100135.
PMID: 39845160
Background: Emergency laparotomy cases account for a significant proportion of the surgical caseload requiring postoperative intensive care. However, access to Intensive Care Unit (ICU) services has been limited by the...
2.
Niccodem E, Majigo M, Nyongole O, Manyahi J, Shangali A, Mwingwa A, et al.
BMJ Open
. 2024 Oct;
14(10):e085580.
PMID: 39461858
Objectives: The objectives are to determine the prevalence of urinary tract infection (UTI) and associated factors among patients diagnosed with benign prostatic hyperplasia and prostate cancer. Design: Hospital-based cross-sectional study....
3.
Mlugu E, Mhagama J, Matiko D, Agustine S, Nandonde M, Masunga E, et al.
Am J Trop Med Hyg
. 2024 Oct;
111(6):1215-1222.
PMID: 39353417
Sustainable access to high-quality antimalarial medicines is pivotal to achieving universal and effective malaria control. Poor-quality antimalarial medicines are prevalent in sub-Saharan Africa, impeding malaria control initiatives and claiming the...
4.
Rugemalila J, Kunambi P, Amour M, Sambu V, Kisonjela F, Rugarabamu A, et al.
Trop Med Int Health
. 2024 Aug;
29(9):792-800.
PMID: 39097978
Background: Adolescents and young adults (AYA) living with HIV have been shown to have lower rates of viral load testing and viral suppression as compared to older adults. We examined...
5.
Fimbo A, Mnkugwe R, Mlugu E, Kunambi P, Malishee A, Minzi O, et al.
Infect Dis Poverty
. 2024 Jun;
13(1):44.
PMID: 38867265
Background: Preventive chemotherapy with ivermectin and albendazole (IA) in mass drug administration (MDA) programs for all at-risk populations is the core public health intervention to eliminate lymphatic filariasis (LF). Achieving...
6.
James M, Naburi H, Mugusi S, Kunambi P, Mwakyandile T, Mnkugwe R, et al.
Antimicrob Agents Chemother
. 2024 May;
68(6):e0149523.
PMID: 38747600
Gentamicin is widely used to treat neonatal infections caused by both Gram-negative and Gram-positive bacteria, and the WHO recommends its use while monitoring serum creatinine and gentamicin concentrations to avoid...
7.
Kilusungu Z, Kassam D, Kimera Z, Mgaya F, Nandolo W, Kunambi P, et al.
Food Addit Contam Part B Surveill
. 2024 Mar;
17(2):161-170.
PMID: 38516743
In Africa, antibiotic residue investigations in animal food have primarily been focused on meat, neglecting farmed fish. This cross-sectional study conducted in Dar es Salaam, Tanzania, aimed to assess sulphonamide...
8.
Fimbo A, Mwalwisi Y, Mwamwitwa K, Matiko D, Mfinanga E, Lyimo J, et al.
Sci Rep
. 2024 Jan;
14(1):615.
PMID: 38182720
Tanzania adopted a Dolutegravir (DTG)-based regimen as first-line treatment in 2019 following the World Health Organization recommendation. Data on the DTG safety profile from sub-Saharan Africa including Tanzania are limited....
9.
Mutagaywa R, Kifai E, Elinisa M, Mayala H, Kisenge P, Shemu T, et al.
Eur J Clin Invest
. 2023 Oct;
54(3):e14114.
PMID: 37874538
Background: Rheumatic heart disease remains the most common cardiovascular disease in children and young adults. The outcome of interventional versus medical therapy on the long term is not fully elucidated...
10.
Fimbo A, Mlugu E, Kitabi E, Kulwa G, Iwodyah M, Mnkugwe R, et al.
CPT Pharmacometrics Syst Pharmacol
. 2023 Aug;
12(12):1884-1896.
PMID: 37638539
Ivermectin (IVM) is a drug of choice used with albendazole for mass drug administration (MDA) to halt transmission of lymphatic filariasis. We investigated IVM pharmacokinetic (PK) variability for its dose...